GSK Updates Market on Total Voting Rights and Share Capital

GlaxoSmithKline ( (GB:GSK) ) has issued an update.

GSK has disclosed that, as of 31 January 2026, its issued share capital comprises 4,316,103,805 ordinary shares, of which 240,019,489 are held in treasury, leaving 4,076,084,316 shares carrying voting rights. The updated voting rights figure provides investors and other market participants with the denominator needed to calculate disclosure thresholds for shareholdings under UK transparency rules, ensuring accurate reporting of significant interests in the company.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, support its growth outlook. However, challenges in cash flow and certain market segments warrant cautious optimism.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK is a global biopharmaceutical company focused on uniting science, technology and talent to develop medicines and vaccines aimed at preventing and treating disease worldwide.

Average Trading Volume: 8,118,971

Technical Sentiment Signal: Buy

Current Market Cap: £75.7B

See more insights into GSK stock on TipRanks’ Stock Analysis page.